Nest survival of Tricolored Blackbirds in California\u27s Central Valley

The Tricolored Blackbird (Agelaius tricolor), almost entirely restricted to California, USA, has recently been proposed for listing under the U.S. Endangered Species Act. Tricolored Blackbirds historically nested in wetlands, but a large proportion of the population now nests in agricultural grain fields where the crop is ready to harvest before the young have fledged. Since 1991, federal agencies have paid farmers to delay harvesting in an effort to increase nesting productivity. However, the relative nesting success of Tricolored Blackbirds breeding in agricultural fields versus wetlands is unknown. Our objectives were to estimate daily survival rate (DSR) of nests, identify habitat covariates that influence nest survival, and estimate the number of young produced per nest. During 2011–2012, we monitored 1,323 Tricolored Blackbird nests in 12 colonies using small temperature data loggers. We modeled DSR using Program RMark with combinations of the following variables: site, habitat type, nest initiation date, nest height, water depth, nest density, colony population size, year, and the proportion of nearby nests that failed. Nest survival varied greatly (range: 0.024–0.719) but was not explained by habitat type. Nest height and nest density were positively associated with DSR. DSR was lowest midway through the breeding season and declined with colony population size. Number of young produced per nest varied by site, was lowest in intermediate-sized colonies of 1,000–5,000 birds, and was highest in 2011. DSR and number of young fledged per nest were similar in agricultural fields and in wetlands. Our results suggest that Tricolored Blackbirds benefit from policies that allow them to complete their nesting cycle in agricultural fields

Kinematics and H_2 morphology of the multipolar Post-AGB star IRAS 16594-4656

context: The spectrum of IRAS 16594-4656 shows shock excited H_2 emission and collisionally excited emission lines such as[O I],[C I],and [Fe II]. aim: The goal is to determine the location of the H_2 and [Fe II] shock emission, to determine the shock velocities,and constrain the physical properties in the shock. methods: High resolution spectra of the H_2 1-0 S(1),H_2 2-1 S(1), [Fe II], and Pa$\beta$ emission lines were obtained with the near infrared spectrograph Phoenix on Gemini South. results: The position-velocity diagrams of H_2 1-0 S(1), H_2 2-1 S(1), and [Fe II] are presented. The H_2 and [Fe II] emission is spatially extended. The collisionally excited [O I] and [C I] optical emission lines have a similar double peaked profile compared to the extracted H_2 profile and appear to be produced in the same shock. They all indicate an expansion velocity of ~8 km/s and the presence of a neutral, very high density region with $n_{\rm e}$ about 3 x 10^6 to 5 x10^7 cm$^{-3}$. The [Fe II] emission however is single peaked. It has a gaussian FWHM of 30 km/s and a total width of 62 km/s at 1% of the peak. The Pa$\beta$ profile is even wider with a gaussian FWHM of 48 km/s and a total width of 75 km/s at 1% of the peak. conclusions: The H$_2$ emission is excited in a slow 5 to 20 km/s shock into dense material at the edge of the lobes, caused by the interaction of the AGB ejecta and the post-AGB wind. The 3D representation of the H_2 data shows a hollow structure with less H_2 emission in the equatorial region. The [Fe II] emission is not present in the lobes, but originates close to the central star in fast shocks in the post-AGB wind or in a disk. The Pa$\beta$ emission also appears to originate close to the star.Comment: 11 pages and 8 figures; A&A in press; the paper includig high resolution figures can be downloaded from http://homepage.oma.be/gsteene/publications.htm

Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder.

Impulse control disorders in Parkinson's disease are common neuropsychiatric complications associated with dopamine replacement therapy. Some patients treated with dopamine agonists develop pathological behaviours, such as gambling, compulsive eating, shopping, or disinhibited sexual behaviours, which can have a severe impact on their lives and that of their families. In this study we investigated whether hypersensitivity to reward might contribute to these pathological behaviours and how this is influenced by dopaminergic medication. We asked participants to shift their gaze to a visual target as quickly as possible, in order to obtain reward. Critically, the reward incentive on offer varied over trials. Motivational effects were indexed by pupillometry and saccadic velocity, and patients were tested ON and OFF dopaminergic medication, allowing us to measure the effect of dopaminergic medication changes on reward sensitivity. Twenty-three Parkinson's disease patients with a history of impulse control disorders were compared to 26 patients without such behaviours, and 31 elderly healthy controls. Intriguingly, behavioural apathy was reported alongside impulsivity in the majority of patients with impulse control disorders. Individuals with impulse control disorders also exhibited heightened sensitivity to exogenous monetary rewards cues both ON and OFF (overnight withdrawal) dopamine medication, as indexed by pupillary dilation in anticipation of reward. Being OFF dopaminergic medication overnight did not modulate pupillary reward sensitivity in impulse control disorder patients, whereas in control patients reward sensitivity was significantly reduced when OFF dopamine. These effects were independent of cognitive impairment or total levodopa equivalent dose. Although dopamine agonist dose did modulate pupillary responses to reward, the pattern of results was replicated even when patients with impulse control disorders on dopamine agonists were excluded from the analysis. The findings suggest that hypersensitivity to rewards might be a contributing factor to the development of impulse control disorders in Parkinson's disease. However, there was no difference in reward sensitivity between patient groups when ON dopamine medication, suggesting that impulse control disorders may not emerge simply because of a direct effect of dopaminergic drug level on reward sensitivity. The pupillary reward sensitivity measure described here provides a means to differentiate, using a physiological measure, Parkinson's disease patients with impulse control disorder from those who do not experience such symptoms. Moreover, follow-up of control patients indicated that increased pupillary modulation by reward can be predictive of the risk of future emergence of impulse control disorders and may thereby provide the potential for early identification of patients who are more likely to develop these symptoms

Effects of STN and GPi Deep Brain Stimulation on Impulse Control Disorders and Dopamine Dysregulation Syndrome

Impulse control disorders (ICDs) and dopamine dysregulation syndrome (DDS) are important behavioral problems that affect a subpopulation of patients with Parkinson's disease (PD) and typically result in markedly diminished quality of life for patients and their caregivers. We aimed to investigate the effects of subthalamic nucleus (STN) and internal globus pallidus (GPi) deep brain stimulation (DBS) on ICD/DDS frequency and dopaminergic medication usage.A retrospective chart review was performed on 159 individuals who underwent unilateral or bilateral PD DBS surgery in either STN or GPi. According to published criteria, pre- and post-operative records were reviewed to categorize patients both pre- and post-operatively as having ICD, DDS, both ICD and DDS, or neither ICD nor DDS. Group differences in patient demographics, clinical presentations, levodopa equivalent dose (LED), and change in diagnosis following unilateral/bilateral by brain target (STN or GPi DBS placement) were examined.28 patients met diagnostic criteria for ICD or DDS pre- or post-operatively. ICD or DDS classification did not differ by GPi or STN target stimulation. There was no change in DDS diagnosis after unilateral or bilateral stimulation. For ICD, diagnosis resolved in 2 of 7 individuals after unilateral or bilateral DBS. Post-operative development of these syndromes was significant; 17 patients developed ICD diagnoses post-operatively with 2 patients with pre-operative ICD developing DDS post-operatively.Unilateral or bilateral DBS did not significantly treat DDS or ICD in our sample, even though a few cases of ICD resolved post-operatively. Rather, our study provides preliminary evidence that DDS and ICD diagnoses may emerge following DBS surgery

An ethnographic study of Latino preschool children's oral health in rural California: Intersections among family, community, provider and regulatory sectors

<p>Abstract</p> <p>Background</p> <p>Latino children experience a higher prevalence of caries than do children in any other racial/ethnic group in the US. This paper examines the intersections among four societal sectors or contexts of care which contribute to oral health disparities for low-income, preschool Latino¹children in rural California.</p> <p>Methods</p> <p>Findings are reported from an ethnographic investigation, conducted in 2005–2006, of family, community, professional/dental and policy/regulatory sectors or contexts of care that play central roles in creating or sustaining low income, rural children's poor oral health status. The study community of around 9,000 people, predominantly of Mexican-American origin, was located in California's agricultural Central Valley. Observations in homes, community facilities, and dental offices within the region were supplemented by in-depth interviews with 30 key informants (such as dental professionals, health educators, child welfare agents, clinic administrators and regulatory agents) and 47 primary caregivers (mothers) of children at least one of whom was under 6 years of age.</p> <p>Results</p> <p>Caregivers did not always recognize visible signs of caries among their children, nor respond quickly unless children also complained of pain. Fluctuating seasonal eligibility for public health insurance intersected with limited community infrastructure and civic amenities, including lack of public transportation, to create difficulties in access to care. The non-fluoridated municipal water supply is not widely consumed because of fears about pesticide pollution. If the dentist brought children into the clinic for multiple visits, this caused the accompanying parent hardship and occasionally resulted in the loss of his or her job. Few general dentists had received specific training in how to handle young patients. Children's dental fear and poor provider-parent communication were exacerbated by a scarcity of dentists willing to serve rural low-income populations. Stringent state fiscal reimbursement policies further complicated the situation.</p> <p>Conclusion</p> <p>Several societal sectors or contexts of care significantly intersected to produce or sustain poor oral health care for children. Parental beliefs and practices, leading for example to delay in seeking care, were compounded by lack of key community or economic resources, and the organization and delivery of professional dental services. In the context of state-mandated policies and procedures, these all worked to militate against children receiving timely care that would considerably reduce oral health disparities among this highly disadvantaged population.</p

Dense gas and the nature of the outflows

We present the results of the observations of the (J,K)=(1,1) and the (J,K)=(2,2) inversion transitions of the NH3 molecule toward a large sample of 40 regions with molecular or optical outflows, using the 37 m radio telescope of the Haystack Observatory. We detected NH3 emission in 27 of the observed regions, which we mapped in 25 of them. Additionally, we searched for the 6{16}-5{23} H2O maser line toward six regions, detecting H2O maser emission in two of them, HH265 and AFGL 5173. We estimate the physical parameters of the regions mapped in NH3 and analyze for each particular region the distribution of high density gas and its relationship with the presence of young stellar objects. From the global analysis of our data we find that in general the highest values of the line width are obtained for the regions with the highest values of mass and kinetic temperature. We also found a correlation between the nonthermal line width and the bolometric luminosity of the sources, and between the mass of the core and the bolometric luminosity. We confirm with a larger sample of regions the conclusion of Anglada et al. (1997) that the NH3 line emission is more intense toward molecular outflow sources than toward sources with optical outflow, suggesting a possible evolutionary scheme in which young stellar objects associated with molecular outflows progressively lose their neighboring high-density gas, weakening both the NH3 emission and the molecular outflow in the process, and making optical jets more easily detectable as the total amount of gas decreases.Comment: 27 pages, 37 figures. Accepted for publication in Astronomy and Astrophysics. Abstract is abridge

Prevention of early childhood caries

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/97473/1/j.1600-0528.1988.tb02094.x.pd

Drug interventions for the treatment of obesity in children and adolescents

BACKGROUND: Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences. OBJECTIVES: To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016. We checked references and applied no language restrictions. SELECTION CRITERIA: We selected randomised controlled trials (RCTs) of pharmacological interventions for treating obesity (licensed and unlicensed for this indication) in children and adolescents (mean age under 18 years) with or without support of family members, with a minimum of three months' pharmacological intervention and six months' follow-up from baseline. We excluded interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes, or included participants with a secondary or syndromic cause of obesity. In addition, we excluded trials which included growth hormone therapies and pregnant participants. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data following standard Cochrane methodology. Where necessary we contacted authors for additional information. MAIN RESULTS: We included 21 trials and identified eight ongoing trials. The included trials evaluated metformin (11 trials), sibutramine (six trials), orlistat (four trials), and one trial arm investigated the combination of metformin and fluoxetine. The ongoing trials evaluated metformin (four trials), topiramate (two trials) and exenatide (two trials). A total of 2484 people participated in the included trials, 1478 participants were randomised to drug intervention and 904 to comparator groups (91 participants took part in two cross-over trials; 11 participants not specified). Eighteen trials used a placebo in the comparator group. Two trials had a cross-over design while the remaining 19 trials were parallel RCTs. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow-up from baseline ranged from six months to 100 weeks.Trials generally had a low risk of bias for random sequence generation, allocation concealment and blinding (participants, personnel and assessors) for subjective and objective outcomes. We judged approximately half of the trials as having a high risk of bias in one or more domain such as selective reporting.The primary outcomes of this review were change in body mass index (BMI), change in weight and adverse events. All 21 trials measured these outcomes. The secondary outcomes were health-related quality of life (only one trial reported results showing no marked differences; very low certainty evidence), body fat distribution (measured in 18 trials), behaviour change (measured in six trials), participants' views of the intervention (not reported), morbidity associated with the intervention (measured in one orlistat trial only reporting more new gallstones following the intervention; very low certainty evidence), all-cause mortality (one suicide in the orlistat intervention group; low certainty evidence) and socioeconomic effects (not reported).Intervention versus comparator for mean difference (MD) in BMI change was -1.3 kg/m(2) (95% confidence interval (CI) -1.9 to -0.8; P < 0.00001; 16 trials; 1884 participants; low certainty evidence). When split by drug type, sibutramine, metformin and orlistat all showed reductions in BMI in favour of the intervention.Intervention versus comparator for change in weight showed a MD of -3.9 kg (95% CI -5.9 to -1.9; P < 0.00001; 11 trials; 1180 participants; low certainty evidence). As with BMI, when the trials were split by drug type, sibutramine, metformin and orlistat all showed reductions in weight in favour of the intervention.Five trials reported serious adverse events: 24/878 (2.7%) participants in the intervention groups versus 8/469 (1.7%) participants in the comparator groups (risk ratio (RR) 1.43, 95% CI 0.63 to 3.25; 1347 participants; low certainty evidence). A total 52/1043 (5.0%) participants in the intervention groups versus 17/621 (2.7%) in the comparator groups discontinued the trial because of adverse events (RR 1.45, 95% CI 0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence). The most common adverse events in orlistat and metformin trials were gastrointestinal (such as diarrhoea, mild abdominal pain or discomfort, fatty stools). The most frequent adverse events in sibutramine trials included tachycardia, constipation and hypertension. The single fluoxetine trial reported dry mouth and loose stools. No trial investigated drug treatment for overweight children. AUTHORS' CONCLUSIONS: This systematic review is part of a series of associated Cochrane reviews on interventions for obese children and adolescents and has shown that pharmacological interventions (metformin, sibutramine, orlistat and fluoxetine) may have small effects in reduction in BMI and bodyweight in obese children and adolescents. However, many of these drugs are not licensed for the treatment of obesity in children and adolescents, or have been withdrawn. Trials were generally of low quality with many having a short or no post-intervention follow-up period and high dropout rates (overall dropout of 25%). Future research should focus on conducting trials with sufficient power and long-term follow-up, to ensure the long-term effects of any pharmacological intervention are comprehensively assessed. Adverse events should be reported in a more standardised manner specifying amongst other things the number of participants experiencing at least one adverse event. The requirement of regulatory authorities (US Food and Drug Administration and European Medicines Agency) for trials of all new medications to be used in children and adolescents should drive an increase in the number of high quality trials

A Key Commitment Step in Erythropoiesis Is Synchronized with the Cell Cycle Clock through Mutual Inhibition between PU.1 and S-Phase Progression

During red blood cell development, differentiation and cell cycle progression are intimately and uniquely linked through interdependent mechanisms involving the erythroid transcriptional suppressor PU.1 and the cyclin-dependent kinase inhibitor p57KIP2